Trial · NCT06919744
Intracranial Venous Stenting Evaluation in Patients With Idiopathic Intracranial Hypertension in the Early Phase
NCT06919744, Not applicable, Recruiting, University Hospital, Montpellier
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intracranial Venous Stenting Evaluation in Patients With Idiopathic Intracranial Hypertension in the Early Phase. Trials, record NCT06919744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06919744
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intracranial Venous Stenting Evaluation in Patients With Idiopathic Intracranial Hypertension in the Early Phase
- NCT number
- NCT06919744
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 114 participants, estimated
- Lead sponsor
- University Hospital, Montpellier
- Conditions
- Idiopathic Intracranial Hypertension (IIH)
- Interventions
- Best medical care, Intervention (stenting)
- First posted
- 2025-04-09
- Last updated
- 2025-10-03
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of patients with resolved papilledema and normalization of intra-cranial pressure | 3 months | Rate of patients with resolved papilledema (defined as Frisén scale grade 0-1 on OCT, without ganglion cells damage, and RNFL ˂ 130 µm) and normalization of intra-cranial pressure (defined as ≤ 25 cm H20 or 18 mmHg measured on lumbar puncture) at 3 months. Papilledema will be studied in the most affected eye. |
| Secondary | HIT-6 grading scale score | 3 and 12 months | Change in mean HIT-6 grading scale score (patient's questionnaire containing 6 questions to evaluate the severity of headache) |
| Secondary | Monthly headache days | 3 and 12 months | Change in monthly headache days (within the last month) reported on patients' dairy |
| Secondary | THI score | 3 and 12 months | Change in THI (Tinnitus Handicap Inventory) score |
| Secondary | Visual field | 3 and 12 months | Change in decibel of Mean Deficit visual field assessed on automated perimetry in both eyes with Humphrey Field Analyzer SITA Standard 24-2 test pattern. Each participant will have at least 2 initial visual field examinations conducted at least 30 minutes apart. The 2 Perimetric Mean Deviation (PMD) measurements will be averaged. |
| Secondary | Visual acuity | 3 and 12 months | Change of visual acuity score evaluated on ETDRS (far vision) at 4 meters and reproducible lighting, and Parinaud scale (near vision) using the best optical correction |
| Secondary | Papilledema | 3 and 12 months | Change of papilledema assessed on Frisen score and RNFL on OCT |
| Secondary | Patient's autonomy | 3 and 12 months | Change in quality of life assessed on EQ5D questionnaire |
| Secondary | Patient's cognition | 12 months | Change in Montreal Cognitive Assessment (MoCA) |
| Secondary | Cognition | 12 months | Change in Trail Making Test (TMT) A and B |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06919744
GET https://conductscience.org/api/trials/v1/NCT06919744/registered